Redefining the treatment pathway for medication‐resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay

Authors

Institutions

Publication Details

Journal
Epilepsia
Published
2026-04-13
DOI
https://doi.org/10.1002/epi.70247
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Redefining the treatment pathway for medication‐resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay

Wesley T. Kerr, Katherine N. McFarlane
Epilepsia
Epilepsy research and treatment
article

Redefining the treatment pathway for medication‐resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay

Wesley T. Kerr, Katherine N. McFarlane
article en

Abstract

No abstract available for this paper.
Epilepsia
University of Pittsburgh (US)
Biohaven Pharmaceuticals, University of Pittsburgh, SK Life Science, National Institute of Neurological Disorders and Stroke
Good health and well-being
Openalex Percentile: Top 16%
Epilepsy research and treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Redefining the treatment pathway for medication‐resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay — Wesley T. Kerr, Katherine N. McFarlane · Epilepsia (2026) | TGRS Research Map | TGRS